UBS Group
ALLO icon

UBS Group’s Allogene Therapeutics ALLO Stock Holding History

UBS Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.32M Buy
3,038,392
+1,434,302
+89% +$3.15M ﹤0.01% 3915
2026
Q1 		$3.91M Buy
1,604,090
+214,497
+15% +$430K ﹤0.01% 4321
2025
Q4 		$1.9M Sell
1,389,593
-2,181,564
-61% -$2.88M ﹤0.01% 5026
2025
Q3 		$4.43M Buy
3,571,157
+1,532,238
+75% +$1.83M ﹤0.01% 4157
2025
Q2 		$2.3M Sell
2,038,919
-104,191
-5% -$138K ﹤0.01% 4664
2025
Q1 		$3.13M Buy
2,143,110
+1,346,619
+169% +$2.54M ﹤0.01% 4272
2024
Q4 		$1.7M Buy
796,491
+449,151
+129% +$1.11M ﹤0.01% 4886
2024
Q3 		$973K Buy
347,340
+47,019
+16% +$125K ﹤0.01% 4682
2024
Q2 		$700K Sell
300,321
-218,880
-42% -$646K ﹤0.01% 4736
2024
Q1 		$2.32M Buy
519,201
+338,006
+187% +$1.41M ﹤0.01% 3795
2023
Q4 		$582K Sell
181,195
-25,564
-12% -$72.5K ﹤0.01% 4986
2023
Q3 		$655K Sell
206,759
-90,253
-30% -$396K ﹤0.01% 4444
2023
Q2 		$1.48M Buy
297,012
+64,501
+28% +$349K ﹤0.01% 3838
2023
Q1 		$1.15M Buy
232,511
+96,631
+71% +$620K ﹤0.01% 3986
2022
Q4 		$855K Sell
135,880
-45,596
-25% -$422K ﹤0.01% 4225
2022
Q3 		$1.96M Buy
181,476
+44,207
+32% +$601K ﹤0.01% 3181
2022
Q2 		$1.56M Sell
137,269
-85,598
-38% -$760K ﹤0.01% 3346
2022
Q1 		$2.03M Buy
222,867
+65,126
+41% +$678K ﹤0.01% 3406
2021
Q4 		$2.35M Sell
157,741
-14,769
-9% -$261K ﹤0.01% 3581
2021
Q3 		$4.43M Buy
172,510
+134,161
+350% +$3.19M ﹤0.01% 2796
2021
Q2 		$1M Sell
38,349
-47,409
-55% -$1.35M ﹤0.01% 4175
2021
Q1 		$3.03M Buy
85,758
+84,515
+6,799% +$2.85M ﹤0.01% 3135
2020
Q4 		$32K Sell
1,243
-199
-14% -$6.49K ﹤0.01% 6569
2020
Q3 		$54K Sell
1,442
-1,537
-52% -$57.9K ﹤0.01% 5589
2020
Q2 		$128K Sell
2,979
-174
-6% -$6.29K ﹤0.01% 5115
2020
Q1 		$62K Buy
3,153
+831
+36% +$19.8K ﹤0.01% 5649
2019
Q4 		$60K Sell
2,322
-1,605
-41% -$44.2K ﹤0.01% 6250
2019
Q3 		$107K Sell
3,927
-56,758
-94% -$1.62M ﹤0.01% 5733
2019
Q2 		$1.63M Buy
60,685
+51,427
+555% +$1.43M ﹤0.01% 3334
2019
Q1 		$268K Buy
9,258
+6,236
+206% +$181K ﹤0.01% 4428
2018
Q4 		$81K Buy
+3,022
New +$80.3K ﹤0.01% 5714

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

UBS Group's ALLO Position: Q2 2026 in Review

UBS Group increased its Allogene Therapeutics (ALLO) stake by 89% in Q2 2026, buying an estimated $3.15M and bringing the position to 3,038,392 shares worth $6.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3915.

UBS Group first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • UBS Group held 3,038,392 shares of Allogene Therapeutics worth $6.32M as of Q2 2026.
  • UBS Group bought 1,434,302 Allogene Therapeutics shares in Q2 2026, an estimated $3.15M.
  • Allogene Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3915 holding.
  • UBS Group first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.